Alembic Pharmaceuticals Limited
Simbolis: APLLTD.NS
NSE
1003.8
INRRinkos kaina šiandien
33.4305
P/E santykis
1.2335
PEG koeficientas
197.31B
MRK kapitalizacija
- 0.01%
DIV pajamingumas
Alembic Pharmaceuticals Limited (APLLTD-NS) Finansinės ataskaitos
Balansas
common:word.in-mln USD Growth | TTM | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | |||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
balance-sheet.row.cash-and-short-term-investments | 4739.2 | 921.2 | 610.9 | 2850.3 | |||||||||||||
balance-sheet.row.short-term-investments | 4804.2 | 166.4 | 316.2 | 1869.7 | |||||||||||||
balance-sheet.row.net-receivables | 22766.1 | 11291.1 | 11900.1 | 8067.3 | |||||||||||||
balance-sheet.row.inventory | 30145.1 | 14752.7 | 16097 | 14861.5 | |||||||||||||
balance-sheet.row.other-current-assets | 5023.9 | 2135.2 | -0.1 | -0.1 | |||||||||||||
balance-sheet.row.total-current-assets | 62674.3 | 29100.2 | 28607.9 | 25779 | |||||||||||||
balance-sheet.row.property-plant-equipment-net | 60805.5 | 29997.3 | 39472.6 | 36480.3 | |||||||||||||
balance-sheet.row.goodwill | 0 | 0 | 0 | 0 | |||||||||||||
balance-sheet.row.intangible-assets | 0 | 0 | 1548.2 | 3229.5 | |||||||||||||
balance-sheet.row.goodwill-and-intangible-assets | 172.2 | 0 | 1548.2 | 3229.5 | |||||||||||||
balance-sheet.row.long-term-investments | 1769.2 | 963.3 | 1184 | 493.1 | |||||||||||||
balance-sheet.row.tax-assets | 2467.1 | 1230.1 | 58.8 | 1108 | |||||||||||||
balance-sheet.row.other-non-current-assets | -1507.4 | 537.4 | 348.8 | -0.1 | |||||||||||||
balance-sheet.row.total-non-current-assets | 63706.6 | 32728.1 | 42612.4 | 41310.8 | |||||||||||||
balance-sheet.row.other-assets | 0.1 | 0 | 0 | 0 | |||||||||||||
balance-sheet.row.total-assets | 126381 | 61828.3 | 71220.3 | 67089.8 | |||||||||||||
balance-sheet.row.account-payables | 14417.6 | 6798.1 | 7063.9 | 6687.7 | |||||||||||||
balance-sheet.row.short-term-debt | 14541.5 | 6527.9 | 6449.7 | 3121.8 | |||||||||||||
balance-sheet.row.tax-payables | 0 | 0 | 0 | 21.5 | |||||||||||||
balance-sheet.row.long-term-debt-total | 1366.4 | 692.3 | 721.4 | 2714.3 | |||||||||||||
Deferred Revenue Non Current | -831.4 | -831.4 | -1976.9 | 855.2 | |||||||||||||
balance-sheet.row.deferred-tax-liabilities-non-current | 831.4 | - | - | - | |||||||||||||
balance-sheet.row.other-current-liab | 1623.4 | 855.4 | -0.1 | 0.2 | |||||||||||||
balance-sheet.row.total-non-current-liabilities | 3507.8 | 1754.3 | 1679.5 | 3611.7 | |||||||||||||
balance-sheet.row.other-liabilities | 0 | 0 | 0 | 0 | |||||||||||||
balance-sheet.row.capital-lease-obligations | 1705.4 | 861.5 | 871.2 | 838.2 | |||||||||||||
balance-sheet.row.total-liab | 37976.2 | 18123.6 | 18844.8 | 16420.1 | |||||||||||||
balance-sheet.row.preferred-stock | 0 | 0 | 0 | 0 | |||||||||||||
balance-sheet.row.common-stock | 786.2 | 393.1 | 393.1 | 393.1 | |||||||||||||
balance-sheet.row.retained-earnings | 35684.4 | 35684.4 | 25543.9 | 24241 | |||||||||||||
balance-sheet.row.accumulated-other-comprehensive-income-loss | 133047.2 | 335.4 | 18808.8 | 18513.8 | |||||||||||||
balance-sheet.row.other-total-stockholders-equity | 7291.8 | 7291.8 | 7629.7 | 8128.2 | |||||||||||||
balance-sheet.row.total-stockholders-equity | 176809.6 | 43704.7 | 52375.5 | 51276.1 | |||||||||||||
balance-sheet.row.total-liabilities-and-stockholders-equity | 214785.8 | 61828.3 | 71220.3 | 67089.8 | |||||||||||||
balance-sheet.row.minority-interest | 0 | 0 | 0 | -606.4 | |||||||||||||
balance-sheet.row.total-equity | 176809.6 | 43704.7 | 52375.5 | 50669.7 | |||||||||||||
balance-sheet.row.total-liabilities-and-total-equity | 214785.8 | - | - | - | |||||||||||||
Total Investments | 6407 | 963.3 | 1184 | 493.1 | |||||||||||||
balance-sheet.row.total-debt | 15907.9 | 7220.2 | 7171.1 | 5836.1 | |||||||||||||
balance-sheet.row.net-debt | 15972.9 | 6465.4 | 6560.2 | 4855.5 |
Pinigų srautų ataskaita
common:word.in-mln USD Growth | TTM | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | |||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
cash-flows.row.net-income | 5902.1 | 3545.9 | 6201.1 | 13680.8 | |||||||||||||
cash-flows.row.depreciation-and-amortization | 2773.1 | 2754.3 | 2867.8 | 1834.7 | |||||||||||||
cash-flows.row.deferred-income-tax | 0 | 0 | 0 | 0 | |||||||||||||
cash-flows.row.stock-based-compensation | 0 | 0 | 0 | 0 | |||||||||||||
cash-flows.row.change-in-working-capital | 0 | -575.6 | -3673.4 | 2395.4 | |||||||||||||
cash-flows.row.account-receivables | 0 | -2228.8 | -4696.2 | 5109.3 | |||||||||||||
cash-flows.row.inventory | 0 | 1344.4 | -1235.5 | -2986.2 | |||||||||||||
cash-flows.row.account-payables | 0 | -281.7 | 366.7 | 452.7 | |||||||||||||
cash-flows.row.other-working-capital | 0 | 590.5 | 1891.6 | -180.4 | |||||||||||||
cash-flows.row.other-non-cash-items | -5902.1 | 1514.9 | 128 | -3277.1 | |||||||||||||
cash-flows.row.net-cash-provided-by-operating-activities | 5546.2 | 0 | 0 | 0 | |||||||||||||
cash-flows.row.investments-in-property-plant-an-equipment | 0 | -4434.1 | -4256.4 | -6595.1 | |||||||||||||
cash-flows.row.acquisitions-net | 0 | 18.7 | 46.1 | -4.6 | |||||||||||||
cash-flows.row.purchases-of-investments | 0 | -70 | -1392.9 | -1861 | |||||||||||||
cash-flows.row.sales-maturities-of-investments | 0 | -18.7 | 1869.7 | 1861 | |||||||||||||
cash-flows.row.other-investing-activites | 0 | 28.2 | 13.8 | -1788.4 | |||||||||||||
cash-flows.row.net-cash-used-for-investing-activites | 0 | -4475.9 | -3719.7 | -8388.1 | |||||||||||||
cash-flows.row.debt-repayment | 0 | -2000 | -3000 | -3792.7 | |||||||||||||
cash-flows.row.common-stock-issued | 0 | 0 | 0 | 7340.8 | |||||||||||||
cash-flows.row.common-stock-repurchased | 0 | 0 | 0 | 0 | |||||||||||||
cash-flows.row.dividends-paid | 0 | -1965.6 | -2751.9 | 0 | |||||||||||||
cash-flows.row.other-financing-activites | 0 | 1346 | 3578.4 | -9522.4 | |||||||||||||
cash-flows.row.net-cash-used-provided-by-financing-activities | 0 | -2619.6 | -2173.5 | -5974.3 | |||||||||||||
cash-flows.row.effect-of-forex-changes-on-cash | 0 | 0 | 0 | -9.3 | |||||||||||||
cash-flows.row.net-change-in-cash | 5546.2 | 143.9 | -369.7 | 262.2 | |||||||||||||
cash-flows.row.cash-at-end-of-period | 7314 | 754.8 | 610.9 | 980.6 | |||||||||||||
cash-flows.row.cash-at-beginning-of-period | 1767.8 | 610.9 | 980.6 | 718.4 | |||||||||||||
cash-flows.row.operating-cash-flow | 5546.2 | 7239.5 | 5523.5 | 14633.8 | |||||||||||||
cash-flows.row.capital-expenditure | 0 | -4434.1 | -4256.4 | -6595.1 | |||||||||||||
cash-flows.row.free-cash-flow | 5546.2 | 2805.4 | 1267.1 | 8038.7 |
Pajamų ataskaitos eilutė
common:word.in-mln USD Growth | TTM | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | |||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
income-statement-row.row.total-revenue | 61181 | 56526.2 | 52317.9 | 52762.2 | |||||||||||||
income-statement-row.row.cost-of-revenue | 17682.1 | 17088.2 | 17231.9 | 15212.7 | |||||||||||||
income-statement-row.row.gross-profit | 43498.9 | 39438 | 35086 | 37549.5 | |||||||||||||
income-statement-row.row.gross-profit-ratio | 0 | 0 | 0 | 0 | |||||||||||||
income-statement-row.row.research-development | 4785.4 | - | - | - | |||||||||||||
income-statement-row.row.selling-general-administrative | 0 | - | - | - | |||||||||||||
income-statement-row.row.selling-and-marketing-expenses | 0 | - | - | - | |||||||||||||
income-statement-row.row.other-expenses | 255.9 | 27.4 | 1.3 | 2 | |||||||||||||
income-statement-row.row.operating-expenses | 37416.9 | 35108.9 | 29160 | 24581.1 | |||||||||||||
income-statement-row.row.cost-and-expenses | 55099 | 52197.1 | 46391.9 | 39793.8 | |||||||||||||
income-statement-row.row.interest-income | 0 | 3.3 | 17.3 | 15.8 | |||||||||||||
income-statement-row.row.interest-expense | 596.2 | 501.7 | 177.3 | 160.2 | |||||||||||||
income-statement-row.row.selling-and-marketing-expenses | 0 | - | - | - | |||||||||||||
income-statement-row.row.total-other-income-expensenet | -479.9 | -831.8 | 379.3 | 1029.8 | |||||||||||||
income-statement-row.row.ebitda-ratio-caps | 0 | - | - | - | |||||||||||||
income-statement-row.row.other-operating-expenses | 255.9 | 27.4 | 1.3 | 2 | |||||||||||||
income-statement-row.row.total-operating-expenses | -479.9 | -831.8 | 379.3 | 1029.8 | |||||||||||||
income-statement-row.row.interest-expense | 596.2 | 501.7 | 177.3 | 160.2 | |||||||||||||
income-statement-row.row.depreciation-and-amortization | 2773.1 | 2754.3 | 2867.8 | 1834.7 | |||||||||||||
income-statement-row.row.ebitda-caps | 9020.8 | - | - | - | |||||||||||||
income-statement-row.row.operating-income | 6131.3 | 4377.8 | 5874.7 | 12968.4 | |||||||||||||
income-statement-row.row.income-before-tax | 5651.5 | 3545.9 | 6201.1 | 13680.8 | |||||||||||||
income-statement-row.row.income-tax-expense | -250.6 | 126.1 | 1044.6 | 2533.2 | |||||||||||||
income-statement-row.row.net-income | 5902.1 | 3419.9 | 5209.4 | 11465 |
Dažnai užduodami klausimai
Kas yra Alembic Pharmaceuticals Limited (APLLTD.NS) bendras turtas?
Alembic Pharmaceuticals Limited (APLLTD.NS) bendras turtas yra 61828300000.000.
Kokios yra įmonės metinės pajamos?
Metinės pajamos yra 32255000000.000.
Kokia yra įmonės pelno marža?
Įmonės pelno marža yra 0.711.
Koks yra įmonės laisvųjų pinigų srautas?
Laisvųjų pinigų srautas yra 28.216.
Kokia yra įmonės grynojo pelno marža?
Grynojo pelno marža yra 0.096.
Kokios yra bendros įmonės pajamos?
Bendrosios pajamos yra 0.100.
Kas yra Alembic Pharmaceuticals Limited (APLLTD.NS) grynasis pelnas (grynosios pajamos)?
Grynasis pelnas (grynosios pajamos) yra 3419900000.000.
Kokia yra bendra įmonės skola?
Bendra skola yra 7220200000.000.
Koks yra veiklos sąnaudų skaičius?
Veiklos sąnaudos yra 35108900000.000.
Koks yra įmonės grynųjų pinigų skaičius?
Įmonės grynieji pinigai yra -1478000000.000.